Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5010, Tv
2. Acetate, Glatiramer
3. Copaxone
4. Glatiramer
5. Tv 5010
6. Tv-5010
7. Tv5010
1. 147245-92-9
2. Acetic Acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic Acid;(2s)-2-aminopentanedioic Acid;(2s)-2-aminopropanoic Acid;(2s)-2,6-diaminohexanoic Acid
3. Glatirameracetat
4. Dtxsid30163637
5. Am84438
6. Ac-28732
7. L-alanine Compound With L-glutamic Acid And L-lysine And L-tyrosine And Acetic Acid (1:1:1:1:1)
8. Q418274
Molecular Weight | 623.7 g/mol |
---|---|
Molecular Formula | C25H45N5O13 |
Hydrogen Bond Donor Count | 12 |
Hydrogen Bond Acceptor Count | 18 |
Rotatable Bond Count | 13 |
Exact Mass | 623.30138651 g/mol |
Monoisotopic Mass | 623.30138651 g/mol |
Topological Polar Surface Area | 374 Ų |
Heavy Atom Count | 43 |
Formal Charge | 0 |
Complexity | 519 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 5 |
1 of 2 | |
---|---|
Drug Name | Copaxone |
PubMed Health | Glatiramer (Injection) |
Drug Classes | Central Nervous System Agent, Immune Suppressant, Musculoskeletal Agent |
Drug Label | Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.... |
Active Ingredient | Glatiramer acetate |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 20mg/ml; 40mg/ml |
Market Status | Prescription |
Company | Teva Pharms Usa |
2 of 2 | |
---|---|
Drug Name | Copaxone |
PubMed Health | Glatiramer (Injection) |
Drug Classes | Central Nervous System Agent, Immune Suppressant, Musculoskeletal Agent |
Drug Label | Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.... |
Active Ingredient | Glatiramer acetate |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 20mg/ml; 40mg/ml |
Market Status | Prescription |
Company | Teva Pharms Usa |
Antirheumatic Agents
Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)
L03AX13
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L03 - Immunostimulants
L03A - Immunostimulants
L03AX - Other immunostimulants
L03AX13 - Glatiramer acetate
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Glatiramer Acetate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Glatiramer Acetate, including repackagers and relabelers. The FDA regulates Glatiramer Acetate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Glatiramer Acetate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Glatiramer Acetate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Glatiramer Acetate supplier is an individual or a company that provides Glatiramer Acetate active pharmaceutical ingredient (API) or Glatiramer Acetate finished formulations upon request. The Glatiramer Acetate suppliers may include Glatiramer Acetate API manufacturers, exporters, distributors and traders.
click here to find a list of Glatiramer Acetate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Glatiramer Acetate DMF (Drug Master File) is a document detailing the whole manufacturing process of Glatiramer Acetate active pharmaceutical ingredient (API) in detail. Different forms of Glatiramer Acetate DMFs exist exist since differing nations have different regulations, such as Glatiramer Acetate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Glatiramer Acetate DMF submitted to regulatory agencies in the US is known as a USDMF. Glatiramer Acetate USDMF includes data on Glatiramer Acetate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Glatiramer Acetate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Glatiramer Acetate suppliers with USDMF on PharmaCompass.
A Glatiramer Acetate written confirmation (Glatiramer Acetate WC) is an official document issued by a regulatory agency to a Glatiramer Acetate manufacturer, verifying that the manufacturing facility of a Glatiramer Acetate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Glatiramer Acetate APIs or Glatiramer Acetate finished pharmaceutical products to another nation, regulatory agencies frequently require a Glatiramer Acetate WC (written confirmation) as part of the regulatory process.
click here to find a list of Glatiramer Acetate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Glatiramer Acetate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Glatiramer Acetate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Glatiramer Acetate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Glatiramer Acetate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Glatiramer Acetate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Glatiramer Acetate suppliers with NDC on PharmaCompass.
Glatiramer Acetate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Glatiramer Acetate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Glatiramer Acetate GMP manufacturer or Glatiramer Acetate GMP API supplier for your needs.
A Glatiramer Acetate CoA (Certificate of Analysis) is a formal document that attests to Glatiramer Acetate's compliance with Glatiramer Acetate specifications and serves as a tool for batch-level quality control.
Glatiramer Acetate CoA mostly includes findings from lab analyses of a specific batch. For each Glatiramer Acetate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Glatiramer Acetate may be tested according to a variety of international standards, such as European Pharmacopoeia (Glatiramer Acetate EP), Glatiramer Acetate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Glatiramer Acetate USP).
LOOKING FOR A SUPPLIER?